Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of GHZ339 in moderate to severe atopic dermatitis
NL-OMON59170Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2026
- Countries
- 1
01
Overview
Phase 2 trial of GHZ339 in atopic dermatitis (AD), sponsored by Novartis. Started Jan 2026; status: recruiting.
02
Drugs
GHZ339
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON59170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59170.